EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy

Thorsten Oliver Goetze, Alexander Stein, Sylvie Lorenzen, Timorshah Habibzada, Eray Goekkurt, Peter Herhaus, Maria Loose iD, Disorn Sookthai, Tanita Brulin, Kristina Ihrig, Claudia Pauligk, Salah-Eddin Al-Batran

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34652 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Thorsten Oliver Goetze und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical Cancer Research IKF, Frankfurt, Germany. Hauptthemen laut MEDLINE: Adenocarcinoma, Stomach Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Lilly Deutschland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Based on results of prior trials (TAGS, REGARD, RAINBOW), the combination of ramucirumab beyond progression with TAS‐102 (trifluridine/tipiracil) seems to be promising in advanced esophagogastric adenocarcinoma (EGA). In this multicenter, non‐randomized, open‐label, investigator‐initiated pilot trial, ramucirumab‐pretreated patients with metastatic EGA received a maximum of 4 cycles of ramucirumab (8 mg/kg i.v. on day 1 and 15, Q2W) plus TAS‐102 (35 mg/m 2 p.o. bid on day 1‐5 and day 8‐12; Q2W). Primary endpoint was tolerability and toxicity, defining a positive trial if the SAE rate according to CTCAE 5.0 will increase

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaStomach NeoplasmsHumansTrifluridineAntineoplastic Combined Chemotherapy ProtocolsTreatment FailureEsophagogastric JunctionRamucirumabDrug CombinationsPyrrolidinesThymine

Stichwörter der Autor:innen

TAS-102metastatic esophagogastric adenocarcinomaramucirumabtreatment beyond progression

Substanzen

TrifluridineRamucirumabtrifluridine tipiracil drug combinationDrug CombinationsPyrrolidinesThymine

Autor:innen und Institutionen

  • Institute for Clinical Cancer Research IKF, Frankfurt, Germany.
  • University Cancer Center Frankfurt, Krankenhaus Nordwest, Frankfurt, Germany.
  • University Cancer Center Frankfurt, Goethe University, Frankfurt, Germany.
  • Hämatologisch-Onkologische Praxis Eppendorf (HOPE) und Universitäres Cancer Center Hamburg (UCCH), Hamburg, Germany.
  • München Klinikum rechts der Isar der TU München III. Medizinische Klinik und Poliklinik, Munich, Germany.

ORCID-Profile: Maria Loose

Förderung

  • Lilly Deutschland

Zitieren

APA

Goetze, T. O., Stein, A., Lorenzen, S., Habibzada, T., Goekkurt, E., Herhaus, P., Loose, M., Sookthai, D., Brulin, T., Ihrig, K., Pauligk, C., & Al-Batran, S. E. (2023). Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.34652

Vancouver

Goetze TO, Stein A, Lorenzen S, Habibzada T, Goekkurt E, Herhaus P, et al. Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy. International Journal of Cancer. 2023. doi:10.1002/ijc.34652

BibTeX
@article{Goetze2023,
  author = {Goetze, Thorsten Oliver and Stein, Alexander and Lorenzen, Sylvie and Habibzada, Timorshah and Goekkurt, Eray and Herhaus, Peter and Loose, Maria and Sookthai, Disorn and Brulin, Tanita and Ihrig, Kristina and Pauligk, Claudia and Al-Batran, Salah-Eddin},
  title = {Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34652}
}
Kostenlos starten →